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SUMMARY
Non-Hodgkin lymphomas of childhood represent a diverse group of neoplasms with different clinical, 
pathological, immunophenotypical and genetic features. A vast majority of childhood non-Hodgkin lym-
phomas could be classified into one of the three major histological subgroups: mature B-cell neoplasms, 
lymphoblastic lymphomas or anaplastic large cell lymphomas. Modern therapeutic strategies lead to cure 
in more than 80% of patients. Conversely, refractory diseases, as well as disease relapse convey a dismal 
prognosis. This fact requires much better stratification based on prognostic markers which would ideally 
recognize distinct groups of patients requiring different therapeutic regimens. Defining novel diagnostic 
and prognostic markers should improve diagnosis and prognosis as well as patient follow-up. It should 
also allow introduction of individually tailored treatment regimens in selected groups of patients with 
non-Hodgkin lymphomas, with the main goal of improving treatment results and decreasing short- and 
long-term complications.
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INTRODUCTION
Lymphomas are neoplasms of lymphoid tissues 
and organs. Lymphoid tissues include single 
lymphocytes located in the epithelium of mu-
cous membranes, aggregates of lymphocytes in 
the skin, gastrointestinal and respiratory tract 
mucosa, or entire organs (i.e., lymph nodes, 
thymus and spleen) strategically located near 
lymphatics and blood vessels. Lymphomas 
can arise in any lymphoid tissue. If they origi-
nate from lymphatic tissues other than lymph 
nodes, they are referred to as extranodal lym-
phomas. In general, staging procedures for 
pediatric non-Hodgkin lymphomas (NHL) 
include computerized tomography (CT) im-
aging of the neck, chest, abdomen, and pelvis, 
bilateral iliac crest bone marrow aspiration and 
biopsy and examination of cerebrospinal fluid. 
After performing the abovementioned inves-
tigations, pediatric NHL are staged according 
to the common Murphy’s staging system [1].
Pediatric lymphomas are usually classified 
as either Hodgkin lymphoma (HL) or as non-
Hodgkin lymphomas, but they are clinically, 
pathologically, and biologically different. Spe-
cific disease entities are classified according to 
the cell lineage of origin (i.e., B-lineage and T-
lineage or natural killer – NK cells) and also, 
according to their origin from precursor or 
mature lymphoid cells. Besides, some types of 
lymphoma are mainly associated with particu-
lar age groups, such as children. Classification 
of lymphoma has evolved over the past dec-
ades from a morphology based scheme to the 
system that integrates morphological, immu-
nophenotypic, genetic, molecular, and clinical 
features into categories adopted for use by pa-
thologists, clinicians and basic scientists. World 
Health Organization (WHO) classification of 
lymphoid neoplasms published in 2001 and 
updated in 2008, represents a universal consen-
sus on the diagnosis of about 70 different forms 
of lymphoma [2]. However, as new discoveries 
are made, and new insights are gained, these 
classifications will continue to evolve with pos-
sible additional modifications.
LYMPHOMAS OF CHILDHOOD
Cancer in children (0-14 years) and adoles-
cents (15-19 years) is rare, contributing to less 
than 1% of the total human cancers. For all 
malignant neoplasms, age-adjusted incidence 
rate is 140 per million for children and 157 per 
million for ages 0-19 years in Europe [3].
Lymphomas are the third most common 
childhood malignancy, preceded only by leuke-
mias and brain tumors. NHL accounts for about 
6% of childhood cancer in patients younger than 
19 years [3]. The incidence of childhood NHL 
varies with age, histology, gender, and race. NHL 
in children is most frequently diagnosed in the 
second decade of life, infrequently in children 
younger than 3 years and very rarely in infants 
[4]. Childhood NHL is more common in males, 
except for primary mediastinal large B-cell lym-
phoma, the incidence of which is almost equal 
between sexes [5]. NHL is rare in Japan but very 
frequent in the African continent, particularly 
the “endemic” Burkitt lymphoma.
Childhood NHLs differ from adult NHL 
regarding disease types, biology, treatment,      
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and outcome. Contrary to adults where NHL is usually 
of low or intermediate grade, in children it is usually dis-
seminated, diffuse not nodular, high grade, rapidly grow-
ing, originating from mature or immature B and T cells, 
with frequent extranodal disease, bone marrow and cen-
tral nervous system (CNS) involvement [2, 6]. Childhood 
NHLs are heterogeneous, however much less comparing 
to adult lymphomas. The subtype distribution significantly 
differs among children and adults. Classification systems 
used for adult lymphomas are complicated due to numer-
ous diagnoses rarely observed in children. About 90% of 
childhood NHL can be categorized into three categories, 
according to WHO classification: 1) mature B cell neo-
plasms (Burkitt lymphoma/leukemia; B-cell lymphoma, 
unclassifiable, with features intermediate between diffuse 
large B-cell lymphoma and Burkitt lymphoma; diffuse 
large B-cell lymphoma (DLBCL) and primary mediastinal 
(thymic) large B-cell lymphoma; 2) precursor lymphoid 
neoplasms (B lymphoblastic leukemia/lymphoma and T 
lymphoblastic leukemia/lymphoma and 3) mature T-cell 
and NK-cell neoplasms (anaplastic large-cell lymphoma – 
ALCL). Other types, rarely seen in children, account for 
about 10% (Table 1) [7].
Treatment results of pediatric lymphomas were ex-
tremely poor a few decades ago. Owing to current treat-
ment regimens, more than 80% of children with NHL will 
be cured. The outcome of treatment varies by a number of 
factors, including clinical stage, histology and genetic stud-
ies [7]. However, treatment results of relapses and refrac-
tory disease are still dismal [8]. Prognostic factors include 
age, localization of the disease, chromosomal alterations, 
tumor burden and response to treatment. The outcome of 
infants [4] and adolescents [9] is poorer as compared to 
young children. Patients with limited disease have excel-
lent outcome. Lactate dehydrogenase (LDH) is a surrogate 
marker for tumor burden, especially in mature B lympho-
mas where it is used as a stratification factor [10]. Minimal 
residual disease (MRD) follow-up is of prognostic value 
in some NHL types. For instance, minimal infiltration of 
bone marrow and peripheral blood is detected in about 
50% of patients with ALCL, using NPM-ALK fusion gene 
by molecular techniques, showing correlation with clini-
cal stage of the disease [11]. The prognostic factor of the 
greatest significance is the choice of adequate treatment 
based on patient’s stratification which requires meticulous 
diagnostic work-up.
MATURE B LYMPHOMAS
Mature B lymphomas are the most common NHL subtype 
contributing to more than 50% of cases (Table 1). Most 
of them are classified as Burkitt lymphoma (BL). Other 
subtypes are less frequent including diffuse large B-cell 
lymphoma (DLBCL) and B-cell lymphoma, unclassifi-
able, with features intermediate between DLBCL and BL 
(intermediate DLBCL/BL). Distinguishing between BL 
and DLBCL in children is not of great significance since 
they do not require different treatment. The distinction 
between BL and intermediate DLBCL/BL is of uncertain 
clinical significance.
BL is usually divided into sporadic or endemic variant, 
and it is characterized by variable clinical manifestations. 
Endemic BL is usually seen among patients in Africa. The 
typical clinical presentation is affection of the jaw or other 
facial bones. The most frequent clinical manifestation of 
sporadic BL is diffuse abdominal mass. Elevated LDH 
which is used as a stratification marker is associated with 
poor prognosis, especially if elevated more than two to 
three times of the upper level of normal for age [10]. Mor-
phologically, BL is a diffuse mature B lymphoma presented 
with monotonous medium sized lymphoid cells, showing 
high proliferation and apoptosis. The microscopic “starry 
sky” appearance is due to scattered macrophages contain-
ing apoptotic tumor cell bodies.
BL is characterized by the expression of surface im-
munoglobulin and other antigens of B cell lineage, such as 
CD 19, CD 20, CD 22 and CD 79a, with a frequent pres-
entation of CD10 [5]. Cytogenetic analysis reveals one of 
three translocations involving c-myc protooncogene. De-
tection of one of these translocations is the gold standard 
for diagnosis. The classical translocation t(8;14)(q24;q32) 
can be detected in about 85% of cases. This translocation 
causes fusion of c-myc, which encodes a transcription 
factor significant for the regulation of cell cycle, with the 
immunoglobulin heavy chain gene locus. In about 15% 
of cases, c-myc is fused with the immunoglobulin kappa 
light chain gene locus [t(2;8)(p11;q24)] or the lambda light 
chain [t(8;22)(q24;q11)] [12]. Other cytogenetic abnor-
malities are associated with a poor outcome. They include 
chromosomes 1q, 7q, or 13q [13].
Patients with localized disease, without CNS or bone 
marrow infiltration have estimated 5-year event-free sur-
vival and 5-year overall survival over 90% [14, 15]. Patients 
Table 1. Current WHO classification and relative frequency of childhood non-Hodgkin lymphomas (NHL)
NHL type Relative 
frequency
Mature B-cell neoplasms
Burkitt lymphoma 40%
Diffuse large B-cell lymphoma with primary mediastinal large B-cell lymphoma 10%
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large 
B-cell lymphoma and Burkitt lymphoma ?
Precursor lymphoid neoplasms
T lymphoblastic lymphoma 20–25%
B lymphoblastic lymphoma 5%
Mature T-cell and NK-cell Anaplastic large-cell lymphoma 10–15%
Rare subtypes 5–10%
NK – natural killer  
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with an advanced stage disease, especially those with CNS 
involvement have poorer prognosis. Successful treatment 
of children with BL is limited regarding research on new 
therapeutics including recombinant anti-CD20 antibody 
(rituximab) which is widely used for the treatment of 
mature CD20+ B cell lymphomas in adults [16]. Rituxi-
mab will be considered in future randomized studies in 
children, especially in patients with advanced disease or 
relapsed/refractory BL.
DLBCL contribute with about 10% of all childhood 
NHL (Table 1). DLBCL are a heterogeneous group of lym-
phomas, and are presented more frequently as a localized 
disease, rarely involving bone marrow and CNS [6]. Dif-
ferent clinical and biological DLBCL variants probably do 
not differ in clinical presentation in children.
DLBCL feature morphologically variable blasts of B-lin-
eage with diffuse infiltration of lymph nodes or extranodal 
sites. Most of them show CD20-positivity. In CD20-negative 
DLBCL, other B-cell marker expression can be detected, 
such as CD79a, CD19, Pax5 or immunoglobulin. Immu-
nophenotyping studies of childhood DLBCL are few [17]. 
Majority of pediatric DLBCL express CD10 and BCL6. 
BCL2 can be detected in about 40% of patients. Breaks 
in BCL2 or BCL2 to IGH fusion by translocation t(14;18) 
(q32;q21) are practically never seen in childhood DLBCL 
[17, 18], as well as BCL6 breaks [18]. However, both BCL2 
and BCL6 proteins can frequently be shown by immunohis-
tochemistry analysis. Other genetic abnormalities are also 
very rare and are limited to single cases only [18].
About one third of pediatric B-NHL, morphologically 
assessed as DLBCL, could be reclassified using gene pro-
filing as molecular BL. This fact suggests that BL is much 
more frequent among childhood B-NHL than defined by 
morphologic evaluation. Again, no difference in treatment 
outcomes has been observed on BFM (Berlin-Frankfurt-
Muenster)-based therapeutic protocols among subgroups 
defined by genetic reclassification [19], however these 
findings may be used for more accurate diagnosis.
The WHO classification of 2008 includes provisional 
borderline categories for cases that are not obviously DL-
BCL or BL. This category, formerly labeled as Burkitt-like 
lymphoma, bears new designation: B-cell lymphoma, un-
classifiable, with features intermediate between DLBCL 
and BL (intermediate DLBCL/BL) [20]. Many cases of in-
termediate DLBCL/BL are diagnosed in adult patients but 
rarely in children [19]. These patients usually present with 
generalized lymphadenopathy or disseminated disease, 
with frequent affection of extranodal sites and frequent 
bone marrow infiltration [19].
Difference between BL and intermediate DLBCL/BL is 
subtle, without clear clinical significance. Contrary to BL, 
cells of intermediate DLBCL/BL show widespread pleo-
morphism, or sporadic presence of single nucleoli in most 
cells. The immunophenotype is comparable to BL: CD19, 
CD20, CD22, CD79a, and germinal center-associated mol-
ecules, CD10 and BCL6. BCL2 expression is variable as 
well as Ki67 labeling index [21].
About one half of intermediate DLBCL/BL exhibit 
8q24/MYC translocations, frequently with atypical fea-
tures: rearrangement with a non-immunoglobulin gene, 
participating in a complex karyotype, and parallel rear-
rangements of the BCL2 and BCL6 genes. These findings 
suggest a “double-hit” or “triple-hit” lymphoma which fea-
tures a second translocation in addition to frequent ones 
i.e. t(8;14), t(8;22), or t(2;8). These lymphomas are almost 
never seen in children as is the case with t(14;18) [22]. 
Previously mentioned gene expression profiling may be 
also of value in defining the molecular signature of inter-
mediate DLBCL/BL.
Despite all of the abovementioned data, children with 
intermediate DLBCL/BL do not have a poor prognosis 
while the prognosis in young adults is not clear [23]. Treat-
ment regimens used for BL and DLBCL in children yield 
high cure rates [14].
LYMPHOBLASTIC LYMPHOMAS
Lymphoblastic lymphomas (LBL) consist of immature 
lymphoid cells. They contribute with approximately 30% 
of all childhood NHL making them the second most fre-
quent NHL subtype (Table 1). The morphology of the cells 
cannot be distinguished from the lymphoblasts of precur-
sor cell acute lymphoblastic leukemia (ALL) i.e. terminal 
deoxynucleotidyl transferase (TdT) positive blasts. LBL are 
primarily differentiated from ALL based on the extent of 
bone marrow infiltration by blast cells. In cases with less 
than 25% bone marrow infiltration, the diagnosis of T-LBL 
is made while in those with 25% or more, the patients are 
diagnosed with ALL [2].
Ninety percent of pediatric LBL are T-LBL [6]. WHO 
classification combines T-LBL and T-ALL into the same, 
single category of T lymphoblastic leukemia/lymphoma. 
Whether they are two distinct entities with overlapping 
characteristics or the same disease, is a subject of ongo-
ing discussion. T-LBL usually presents with an anterior 
mediastinal mass whereas T-ALL predominantly presents 
with bone marrow disease causing peripheral blood ab-
normalities [6]. These two entities might be biologically 
different as suggested by some slight immunophenotypic, 
cytogenetic and molecular distinctions [24]. Cure rates for 
T-LBL are high, nearing 80%, using contemporary chemo-
therapy regimens for ALL [25, 26, 27]. However, estab-
lished prognostic markers in T-ALL, such as prednisone 
response, BM response and MRD evaluation cannot be 
used in patients with T-LBL [24], and thus a reliable pre-
treatment stratification of T-LBL patients is not possible. 
Furthermore, data about useful prognostic markers in T-
LBL are limited.
Generally, immunophenotype of T-LBL is similar to 
T-ALL; TdT positivity and combination of T-cell antigens 
such as CD2, CD5, and CD7 in most of the cases [28]. 
Cytoplasmic and/or surface CD3 is positive in nearly all 
T-LBL cases, while CD4 and CD8 are positive in more 
than 70%. Contrary to T-ALL, frequent CD4/CD8 dou-
ble positivity as well as CD1a positivity suggests deriva-
tion of T-LBL from a more mature thymocyte stage [29]. 
Sometimes, aberrant myeloid antigen expression (CD33      
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and CD13) is present [30] as well as co-expression of B-cell   
antigens or stem-cell markers. Small minority of T-LBL   
does not express TdT. However, these features do not 
convey inferior outcome in T-LBL [28]. For that reason, 
immunophenotype is important for diagnosis but not for 
prognosis in childhood T-LBL.
Chromosomal abnormalities in childhood T-LBL are 
not clearly defined, however common aberrations seen in 
T-ALL are also found in T-LBL [29] and they are not used 
as a stratification tool.
Many oncogenic markers are described in patients with 
T-ALL/T-LBL, however they are only present in a small 
number of patients, without clear prognostic value. Loss 
of heterozygosity (LOH) at chromosome 6q16, mutations 
of NOTCH1 as well as F-box and WD40 domain protein 
7 (FBXW7) mutations show most potential as prognos-
tic markers. LOH at 6q was reported as an unfavorable 
prognostic marker with an increased risk of relapse among 
108 patients with T-LBL, in a recent study [31]. In this 
study, 19% patients with LOH at chromosome 6 had an 
associated 5-year cumulative incidence of relapse greater 
than 60%. Another prognostic marker, NOTCH1 is a gene 
encoding a receptor included in the regulation of T-cell 
development. Its mutation has been reported in more 
than half of T-ALLs [32]. Alternatively, FBXW7 protein, 
which plays a critical role in intracellular degradation of 
NOTCH1, is also implicated as a prognostic factor in T-
ALL. Mutations in NOTCH1/FBXW7 were reported as 
a good prognostic factor in a study of 54 children with 
T-LBL [33]. More than half of patients in the study bore 
mutations that conveyed improved event-free survival and 
overall survival in this subgroup. Similar findings in 64% 
among 113 patients with T-LBL were published by a NHL-
BFM study group, again with favorable prognosis [34]. The 
ongoing research of the NHL-BFM group will include 
these alterations into patient stratification. A recent study 
analyzed LOH6q and NOTCH1/FBXW7 mutations in 217 
children with T-LBL [35]. Twelve percent of patients with 
LOH6q had a lower event-free survival (EFS) compared 
to those without this alteration, while 60% of patients with 
NOTCH1 mutations had a higher EFS when compared to 
patients without mutation. Future trials are needed with 
the aim of decreasing treatment intensity in low risk pa-
tients while increasing or introducing new targeted treat-
ment regimens in high-risk patients with T-LBL, defined 
by the aforementioned newly discovered genetic markers. 
Another aspect of treatment individualization is repre-
sented by the current use of pharmacogenomic markers 
such as gene polymorphisms important for metabolism 
of drugs. One of these pharmacogenomic markers is the 
detection of TPMT gene polymorphisms correlating with 
the metabolism and toxicity of thiopurine drugs [36, 37].
ANAPLASTIC LARGE CELL LYMPHOMAS
ALCL contribute with up to 15% of all pediatric NHL (Ta-
ble 1). This lymphoma subtype usually manifests aggres-
sively, while extranodal involvement may be present or 
absent. Characteristic manifestation includes lymphaden-
opathy with possible involvement of skin or involvement 
of subcutaneous tissues, with frequent fever and constitu-
tional symptoms [6]. Mediastinal mass and involvement 
of viscera and skin are recognized as factors of inferior 
prognosis [38]. Three morphological variants of ALCL are 
defined in the WHO classification; common variant, with 
typical large anaplastic cells, lymphohistiocytic variant and 
small cell variant [2]. The latter two variants convey infe-
rior prognosis [39]. One of the hallmarks of ALCL present 
in most pediatric cases is the translocation t(2;5)(p23;q35). 
This translocation produces the fusion of the nucleophos-
min gene (NPM) at chromosome 5q35 and anaplastic lym-
phoma kinase gene (ALK) at 2p23 position. Children and 
young adults are characteristically affected by the ALK+ 
ALCL which results in better prognosis as compared to 
ALK-ALCL [40]. ALK negative form of ALCL is limited 
only to single case reports or small case series in children. 
Using anti-ALK antibodies is a golden standard which 
makes the diagnosis of ALK+ALCL straightforward and 
readily available [41]. About 10-30% of patients show 
initial BM involvement on conventional morphology and 
immunophenotyping. Using molecular genetics seems to 
be more sensitive, detecting more than half of cases [11]. 
However, peripheral blood count alterations are usually 
rare but they are mostly found in children with ALK+ 
small cell variant [42].
Anaplastic cells showing T/null immunophenotype 
are typically proliferated in ALCL and they express Ki-1 
(CD30) antigen. Cells of this lymphoma subtype usually 
show CD4 as a T-cell activation marker, although with a 
loss of pan–T-cell antigens, mostly CD3 as a manifestation 
of defective T-cell signalling [43]. T-cell origin of this neo-
plasm may be confirmed by immunostaining for CD43, 
CD45RO, CD2, CD4, CD5, CD7, and CD8. The latter anti-
gen is positive in only few ALCL. Most ALK+ ALCL reveal 
clonal rearrangement of T-cell receptor (TCR) gene. The 
absence of the abovementioned T-cell antigens in other-
wise typical ALCL is deemed “null” phenotype [44, 45]. 
Around 10% of ALCLs show a simultaneous presence of 
B-cell clone [45]. On the other hand, myeloid antigen ex-
pression such as CD13 and CD33 can be detected in a 
vast majority of ALCLs [46] erroneously suggesting the 
diagnosis of acute leukemia. The typical anaplastic large 
cells usually show positivity for epithelial membrane an-
tigen (EMA+) and T-cell intracellular antigen 1 (TIA-1+).
NPM-ALK rearrangement detected by PCR is repre-
sentative for ALCL and can be used for the diagnosis and 
confirmation of BM infiltration at submicroscopic level. 
Different morphological types of ALCL have different gene 
expression profiles. The genes involved are important for 
the regulation of cell cycle, cell proliferation, adhesion and 
migration. Secondary genomic imbalances can be detected 
in more than half of ALK+ALCLs. A lower number of 
these secondary aberrations correlate with better survival 
[47]. However, there are studies which have not confirmed 
this fact [48].
ALK+ALCL treated with the usual chemotherapy based 
on regimens for mature B-cell lymphomas, have a good   
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prognosis with 5-year EFS − up to 75% [7]. Research in 
proteomics recognized alterations in proteins included ALK 
signaling pathway [49], however without clear pathogenetic 
role. If proven significant, they may become targets for novel 
therapeutic agents. Available novel therapies are being tested 
in randomized trials and include small-molecule inhibitor 
of the receptor tyrosine kinases, crizotinib and antibody-
drug conjugate against CD30, brentuximab vedotin [50]. 
Additionally, immune therapy with anti-ALK vaccine may 
also become reality since ALK is not normally expressed 
in human cells, except for central nervous system. ALK 
is known to be immunogenic since most patients with 
ALK+ALCL have detectable anti-ALK antibodies [51].
CONCLUSION
Pediatric non-Hodgkin lymphomas are very heterogeneous 
in terms of morphology, immunophenotype, genetic altera-
tions, therapy response and risk of relapse. Excellent im-
provement in treatment results has been achieved thanks to 
understanding of these characteristics. On the other hand, 
the relapsed or refractory disease conveys much poorer 
prognosis. This fact requires much better stratification 
based on still undefined prognostic markers which would 
ideally recognize distinct groups of patients requiring dif-
ferent therapeutic regimens. In this setting, selected patients 
may be offered less toxic regimens while more aggressive 
treatment or novel targeted therapeutics could be reserved 
for patients with poor prognostic parameters and for those 
who do not respond to conventional treatment. These two 
groups of pediatric patients with NHL cannot be readily dis-
tinguished by prognostic markers used nowadays. Defining 
novel diagnostic and prognostic markers should improve di-
agnosis and prognosis as well as patient follow-up. It should 
also allow introduction of individually tailored treatment 
regimens in selected groups of patients with NHL, with the 
main goal of improving treatment results and decreasing 
short- and long-term complications. 
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КРАТАК САДРЖАЈ
Пе  ди  ја  триј  ски не  хоч  кин  ски лим  фо  ми су ра  зно  род  на гру  па 
ма  лиг  ни  те  та с раз  ли  чи  тим кли  нич  ким, па  то  ло  шким, иму  но-
фе  но  тип  ским и ге  нет  ским осо  би  на  ма. Ве  ћи  на не  хоч  кин  ских 
лим  фо  ма деч  јег до  ба се мо  же кла  си  фи  ко  ва  ти у јед  ну од три 
глав  не хи  сто  ло  шке ка  те  го  ри  је: зре  ле Б-нео  пла  зме, лим  фо-
бласт  не лим  фо  ме и круп  но  ће  лиј  ске ана  пла  стич  не лим  фо  ме. 
Са  вре  ме  ним те  ра  пиј  ским при  сту  пом се по  сти  же из  ле  че  ње 
код ви  ше од 80% бо  ле  сни  ка. С дру  ге стра  не, бо  лест ко  ја не 
од  го  во  ри на те  ра  пи  ју и ре  ци  ди  ви има  ју ло  шу прог  но  зу. Сто-
га је нео  п  ход  но бо  ље разврставање бо  ле  сни  ка за  сно  ва  но 
на прог  но  стич  ким мар  ке  ри  ма, ко  ји би иде  ал  но тре  ба  ло да 
раз  дво  је раз  ли  чи  те гру  пе бо  ле  сни  ка ко  ји  ма је по  треб  на 
дру  га  чи  ја те  ра  пи  ја. Де  фи  ни  са  ње но  вих ди  јаг  но  стич  ких и 
прог  но  стич  ких мар  ке  ра би тре  ба  ло да по  бољ  ша ди  јаг  но  зу, 
прог  но  зу, пра  ће  ње бо  ле  сти и уво  ђе  ње ин  ди  ви  ду  а  ли  зо  ва-
ног те  ра  пиј  ског при  сту  па код ода  бра  них бо  ле  сни  ка, ра  ди 
по  бољ  ша  ња ре  зул  та  та ле  че  ња и сма  ње  ња не  по  сред  них и 
по  зних по  сле  ди  ца ле  че  ња.
Кључ  не ре  чи: не  хоч  кин  ски лим  фом; де  ца; кла  си  фи  ка  ци  ја; 
ди  јаг  но  за; прог  но  за; те  ра  пи  ја
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